Poor benefit/risk balance of intravenous immunoglobulins in DRESS

Arch Dermatol. 2012 Apr;148(4):543-4. doi: 10.1001/archderm.148.4.dlt120002-c.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Aged
  • Cytomegalovirus / physiology
  • Disease Progression
  • Drug Eruptions / drug therapy*
  • Drug Eruptions / immunology
  • Drug Eruptions / virology
  • Eosinophilia / drug therapy*
  • Eosinophilia / immunology
  • Eosinophilia / virology
  • Female
  • Fever / etiology
  • Herpesvirus 4, Human / physiology
  • Herpesvirus 6, Human / physiology
  • Herpesvirus 7, Human / physiology
  • Humans
  • Immunoglobulins, Intravenous / adverse effects*
  • Immunoglobulins, Intravenous / therapeutic use
  • Interferon-gamma / blood
  • Male
  • Middle Aged
  • Prospective Studies
  • Remission Induction
  • Risk Assessment
  • Tumor Necrosis Factors / blood
  • Virus Activation*

Substances

  • Adrenal Cortex Hormones
  • Immunoglobulins, Intravenous
  • Tumor Necrosis Factors
  • Interferon-gamma